Studies on therapeutic effects and pathological features of an antithrombin preparation in septic disseminated intravascular coagulation patients

Yonsei Medical Journal

Volumn 54, Issue 3, 2013, Pages 686-689

  Sakamoto, Yuichiro ^a   Inoue, Satoshi ^a   Iwamura, Takashi ^a   Yamashita, Tomoko ^a   Nakashima, Atsushi ^a   Nishimura, Yoichi ^a   Koami, Hiroyuki ^a   Imahase, Hisashi ^a   Goto, Akiko ^a   Yamada, Kosuke Chris ^a   Mashiko, Kunihiro ^b   Yokota, Hiroyuki ^c  

^a SAGA UNIVERSITY HOSPITAL   (Japan)

^b NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Antithrombin; DIC; Sepsis

Indexed keywords

ANANDAMIDE; ANTITHROMBIN; BLOOD CLOTTING FACTOR; CYTOKINE; INTERLEUKIN 5; INTERLEUKIN 7; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C;

ADULT; APACHE; ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FIBRINOGEN METABOLISM; FIBRINOLYSIS; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PROTHROMBIN TIME; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; TREATMENT OUTCOME;

ANTITHROMBIN; DIC; SEPSIS;

AGED; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; SEPSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875883640     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2013.54.3.686     Document Type: Article

References (17)

1. Kushimoto S, Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, et al. Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. Comparison between sepsis and trauma. Thromb Haemost 2008;100:1099-1105.
2. Petros S, Kliem P, Siegemund T, Siegemund R. Thrombin generation in severe sepsis. Thromb Res 2012;129:797-800.
3. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-873.
4. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
5. Bernard GR, Vincent JL, Laterre PF, LaRosa S P, Dhainaut JF, Lopez-Rodriguez A, et al. Effcacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
6. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055-2064.
7. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, et al. A multicenter, prospective validation of disseminated intravas-cular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006;34:625-631.
8. Wagner DP, Draper EA. Acute physiology and chronic health evaluation (APACHE II) and Medicare reimbursement. Health Care Financ Rev 1984;Suppl:91-105.
9. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bru-ining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22: 707-710.
10. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards defnition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-1330.
11. Wada H, Sase T, Matsumoto T, Kushiya F, Sakakura M, Mori Y, et al. Increased soluble fbrin in plasma of patients with disseminated intravascular coagulation. Clin Appl Thromb Hemost 2003; 9:233-240.
12. Silva E, de Figueiredo LF, Colombari F. Prowess-shock trial: a protocol overview and perspectives. Shock 2010;34 Suppl 1:48-53.
13. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998;24:663-672.
14. Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998; 24:336-342.
15. Wiedermann CJ, Kaneider NC. A systematic review of antithrom-bin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis 2006;17: 521-526.
16. Welcker K, Lederle J, Schorr M, Siebeck M. Surgery and adjuvant therapy in patients with diffuse peritonitis: cost analysis. World J Surg 2002;26:307-313.
17. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Hae-most 2006;4:90-97.